Developing new drugs to treat brain tumours

Developing new drugs to treat the brain

Details.

Title of the patent: Developing new drugs to treat brain tumours
Territories filed: Europe, Australia, China, Canada, United States
Status: Pending
Published as: WO2014049364A1
Licensing status: Ready for exploitation
Priority filing date: 27th September 2012

Introduction

UCLan has developed and patented a series of new molecules that we hope one day could be advanced into a much needed new treatment for malignant brain tumours. Current prognosis for such patients is very poor and our continued aim is to invent better drugs to treat the disease.

Description

​UCLan is working on the development of new compounds for use as therapeutic agents, particularly in the treatment and/or prevention of proliferative disorders, such as cancer, especially brain cancers/ tumours. The work scope includes the development of pharmaceutical compositions and specific therapeutic uses of the compounds.

Proliferative disorders, such as cancer, are caused by uncontrolled and unregulated cellular proliferation. Wide ranging research has over the years lead to the development of numerous anticancer drug treatments, though it is becoming increasingly recognised that particular types of cancers need to be targeted with particular drugs. As such, chemotherapy research is increasingly focussing on specific treatments for specific types of cancer rather than generic cancer treatments.

The discovery of alternative and efficacious drug treatments for brain cancers and brain tumours has proved particularly challenging for researchers. For instance, to be effective, such drugs must be capable of penetrating the blood-brain barrier, and be efficacious whilst minimising undesirable side-effects. Brain cancer drugs currently in use include inter alia Cisplatin,Temozolomide, Etoposide, and Carmustine. Amongst these particular drugs, Cisplatin has been shown to possess the best cytotoxic effects against established glioma cell lines 1321N1 (WHO Grade 2) and U87MG (WHO Grade 4).[1] It is thought that Cisplatin derives its therapeutic activity against brain cancers from DNA-alkylation behaviour.

Core Advantages

  1. The current work aims to provide an alternative therapeutic treatment of proliferative disorders such as brain cancers.
  2. The work is focussed on a drug which operates, at least in part, via a mode of action dissimilar to drugs of the prior art, such as Cisplatin.
  3. The technology has the potential to provide a drug which is suitable for treating proliferative disorders, such as brain cancers, and is straightforward to synthesize.

Application

Treatment and/or prevention of proliferative disorders, such as cancer, especially brain cancers/tumours.

Our approach provides a method of inhibiting growth of either or both U87MG and 1321N1 cell lines in vitro or in vivo, provides a method of inhibiting cell proliferation, in vitro or in vivo, provides a method of treating a proliferative disorder or cancer in a patient in need of such treatment.

The focus of our work is the treatment of brain cancers and/or brain tumours in particular glioma.

Contact

To discuss this patent please contact innovationteam@uclan.ac.uk

Patent available to view on: Espacenet